Sanofi Q3 2026 non-IFRS business EPS rises 22% to €3.55

Bitget2026/10/30 06:31

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Sanofi’s Q3 2026 non-IFRS business EPS rose 22% to €3.55.
Net sales climbed 16% to €14.44 billion.
An expanded Regeneron alliance opens further immunology opportunities, while a Cheplapharm partnership covers legacy medicines.
Strong commercial and financial momentum prompted an upgrade to FY26 guidance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610300230PRIMZONEFULLFEED1001280793) on October 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Sanofi Q3 2026 non-IFRS business EPS rises 22% to €3.55

You may also like

Crypto prices